Publications by authors named "Nicola C Maciocia"
Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell lymphomas and leukaemias. This success has inspired the development of CAR-T for T cell malignancies. T cell lymphomas and T-ALL are highly heterogenous diseases but are united by poor prognosis in the relapsed/refractory (r/r) setting and the lack of any novel, targeted therapies.
View Article and Find Full Text PDFArticle Synopsis
- - T cell acute lymphoblastic leukemia (T-ALL) is a severe cancer of immature T lymphocytes, with a higher chance of treatment failure compared to B cell acute lymphoblastic leukemia, making effective treatment difficult.
- - Immunotherapies that work well for B cell leukemia face challenges in T-ALL due to the lack of unique target antigens on malignant T cells and the harmful effects of depleting healthy T cells.
- - The study identifies the CCR9 chemokine receptor as present in over 70% of T-ALL cases, and proposes that CAR T-cells targeting CCR9 could be a promising treatment, offering potent anti-leukemic effects without the serious side effects associated with current therapies.